EGA appoints new Director General

Adrian van den Hoven takes up the role

Adrian van den Hoven joins the European Generic Medicines Association (EGA) today (2 September) in the role of Director General.

Van den Hoven comes to the EGA from the position of Deputy-Director General at BusinessEurope where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor).

Beata Stepniewska, Deputy Director General, who has been Acting Director General for the past eight months, says she is looking forward to a successful collaboration with van den Hoven.

You may also like

Regulatory

EGA outlines priorities in TTIP negotiations between EU and US

Also calls on EU to agree to set up quality testing, pharmacovigilance systems and regulatory agency in Africa
Regulatory

Biosimilars need the same names as original biologics

Proper naming of biosimilars is key for patient access and safety, say delegates at WHO INN meeting
Pharmaceutical

EGA seeks EU-wide strategy to boost generic and biosimilar medicines sectors

Companies represented within the EGA provide more than 150,000 jobs in Europe
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Subscribe now